These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 18301075)

  • 1. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation.
    Moreno A; Bárcena R; Quereda C; Casado JL; Pérez-Elías MJ; Fortún J; Nuño J; Arranz I; Moreno S
    AIDS; 2008 Feb; 22(4):547-8. PubMed ID: 18301075
    [No Abstract]   [Full Text] [Related]  

  • 2. Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
    Cabrera C
    Curr Opin Investig Drugs; 2008 Aug; 9(8):885-98. PubMed ID: 18666037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial will evaluate a once-daily dose of raltegravir.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918-9. PubMed ID: 19043842
    [No Abstract]   [Full Text] [Related]  

  • 4. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltegravir treatment response in an HIV-2 infected patient: a case report.
    Garrett N; Xu L; Smit E; Ferns B; El-Gadi S; Anderson J
    AIDS; 2008 May; 22(9):1091-2. PubMed ID: 18520356
    [No Abstract]   [Full Text] [Related]  

  • 7. Raltegravir, a new HIV integrase inhibitor.
    Gandhi RT
    AIDS Clin Care; 2007 Dec; 19(12):105. PubMed ID: 18399003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
    Summa V; Petrocchi A; Bonelli F; Crescenzi B; Donghi M; Ferrara M; Fiore F; Gardelli C; Gonzalez Paz O; Hazuda DJ; Jones P; Kinzel O; Laufer R; Monteagudo E; Muraglia E; Nizi E; Orvieto F; Pace P; Pescatore G; Scarpelli R; Stillmock K; Witmer MV; Rowley M
    J Med Chem; 2008 Sep; 51(18):5843-55. PubMed ID: 18763751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus conversion for renal preservation in liver transplantation: not so fast.
    Jensen GS; Wiseman A; Trotter JF
    Liver Transpl; 2008 May; 14(5):601-3. PubMed ID: 18433068
    [No Abstract]   [Full Text] [Related]  

  • 10. Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.
    Di Biagio A; Rosso R; Siccardi M; D'Avolio A; Bonora S; Viscoli C
    J Antimicrob Chemother; 2009 Oct; 64(4):874-5. PubMed ID: 19643773
    [No Abstract]   [Full Text] [Related]  

  • 11. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
    Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
    Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA notifications. Accelerated approval for raltegravir tablets.
    AIDS Alert; 2007 Dec; 22(12):143-4. PubMed ID: 18411485
    [No Abstract]   [Full Text] [Related]  

  • 16. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
    Roquebert B; Blum L; Collin G; Damond F; Peytavin G; Leleu J; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
    AIDS; 2008 Oct; 22(15):2045-6. PubMed ID: 18784469
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution.
    Masiá M; Enríquez R; Sirvent A; Gutiérrez F
    J Infect; 2010 Jul; 61(2):189-90. PubMed ID: 20447415
    [No Abstract]   [Full Text] [Related]  

  • 18. [Raltegravir as first integrase inhibitor in an HIV-infection].
    Papendorp SG; Brinkman K
    Ned Tijdschr Geneeskd; 2009 Jan; 153(5):166-7. PubMed ID: 19256240
    [No Abstract]   [Full Text] [Related]  

  • 19. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of antiviral activity in drugs for HIV-1.
    Siliciano RF
    Lancet Infect Dis; 2011 Dec; 11(12):888-9. PubMed ID: 21933753
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.